focus -WSS

focus

author：entertainment 2025-09-28 05:04:32 - browse：95376

novavax photo illo — JUSTIN TALLIS/AFP via Getty Images

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, all. Damian here with an update on the plight of the other Covid-19 vaccine company, Wall Street’s latest GLP-1 trade, and the quest for a universal antivenom.

The need-to-know this morning

Ocular Therapeutics announced a shakeup of its senior management team and a $325 million private placement.
Amylyx Therapeutics said results from a closely followed Phase 3 study of its treatment for ALS could come before the start of the second quarter — earlier than previously expected.
Moderna earnings are here.

Novavax’s money is going in the wrong direction

The good news for Novavax is that it’s no longer facing a $700 million dispute with a global charity organization. The bad news is that settling that dispute will force the struggling company to pay out $400 million over the next five years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Inari Medical to buy amputation prevention company LimFlow

focus

WSS

Explaining an after

3 trends to watch in health tech's hiring outlook for 2024

AdventHealth escalates lawsuit against insurance vendor Multiplan

Ahead of JPM, here's who's profiting most in health care

A single drug, study failures leave Anavex with nothing but cash

What is microchimerism and how does it affect maternal health?

knowledge

focus

The need-to-know this morning

Novavax’s money is going in the wrong direction

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Kidney transplant patients stopped immunosuppressants in trial

ChatGPT in medicine: STAT answers readers' burning questions

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Medicare proposal to cover medical devices draws a mixed reaction

AdventHealth escalates lawsuit against insurance vendor Multiplan

Affirmative action in medical school literally saved lives

Ahead of JPM, here's who's profiting most in health care

Anesthesiologist group: stop taking Ozempic before surgery

Humans aren't the only ones with an imagination. Rats have it too

hotspot

Prime Medicine says its gene editing passes test in monkeys

Ahead of JPM, here's who's profiting most in health care

Gene therapy’s promise and the high cost of hope

Live blog: Hearing on CRISPR

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

JPM: CVS says Medicare Advantage patients are impacting profits

leisure time

leisure time

focus

Wikipedia